Showing 3691-3700 of 4107 results for "".
- Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Studyhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-to-meet-with-fda-on-operational-aspects-of-pv-10-phase-3-melanoma-study/2459043/Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be me
- Vivacare Launches "Find a Dermatologist" Directory with "Expert Opinion" Functionhttps://practicaldermatology.com/news/vivacare-launches-find-a-dermatologist-directory-with-expert-opinion-function/2459044/Vivacare has launched its new <a href="http://www.findadermatologist.com" target="_blank">Find a Dermatolog
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- DermSpectra Releases Total Body Digital Skin Imaging Systemhttps://practicaldermatology.com/news/dermspectra-releases-its-total-body-digital-skin-imaging-system/2459052/DermSpectra realease its DermSpectra Total Body Digital Skin Imaging System, which enables physicians to monitor critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) over time. The DermSpectra advanced medical technology allows physicians to digitally capture and compare s
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Data for COMBI-v Study Now Publishedhttps://practicaldermatology.com/news/20141117-data_for_combi-v_study_now_published/2459059/Data demonstrating that treatment with the combination of trametinib (Mekinist™) and dabrafenib (Tafinlar™) significantly improved overall survival (OS) compared to vemurafenib monotherapy in previously untreated patients with BRAF V600E/K mutation-positive metastatic melanoma, without increased ov
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou
- Cetaphil Brand Revamps RestoraDerm Product Linehttps://practicaldermatology.com/news/20141117-cetaphil_brand_revamps_restoraderm_product_line/2459061/Galderma Laboratories, LP unveiled a new and improved look for their Cetaphil RestoraDerm product line. The new look brings eczema to the forefront of the packaging featuring their new names, Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming M